USA-headquartered health care major Abbott Laboratories has commented on the UK National Institute of Health and Clinical Excellence's (NICE) guidance on anti-obesity prescribing (Marketletter June 30), noting that it reinforces its own product Reductil (sibutramine) and orlistat (Swiss drug major Roche's Xenical) as the preferred, first-line therapies for treating obesity and acknowledges rimonabant (French drug major Sanofi-Aventis' Acomplia) as a second-line option for patients who have had an inadequate response to, or are intolerant or contraindicated to the primary options. Reductil and orlistat are already recommended by the NICE as cost-effective treatments of obesity.
Reductil has been used by more than 20 million people worldwide for the treatment of obesity and was involved in more than 100 clinical studies with more than 19,000 patients. The safety of the product has been evaluated by both the US Food and Drug Administration and the European Medicines Agency (EMEA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Abbott comments on NICE obesity drug guidance
USA-headquartered health care major Abbott Laboratories has commented on the UK National Institute of Health and Clinical Excellence's (NICE) guidance on anti-obesity prescribing (Marketletter June 30), noting that it reinforces its own product Reductil (sibutramine) and orlistat (Swiss drug major Roche's Xenical) as the preferred, first-line therapies for treating obesity and acknowledges rimonabant (French drug major Sanofi-Aventis' Acomplia) as a second-line option for patients who have had an inadequate response to, or are intolerant or contraindicated to the primary options. Reductil and orlistat are already recommended by the NICE as cost-effective treatments of obesity.
Reductil has been used by more than 20 million people worldwide for the treatment of obesity and was involved in more than 100 clinical studies with more than 19,000 patients. The safety of the product has been evaluated by both the US Food and Drug Administration and the European Medicines Agency (EMEA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze